Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Langerhans cell histiocytosis


Other Names for this Disease
  • LCH
  • Histiocytosis X
  • Eosinophilic granuloma (formerly)
  • Letterer-Siwe disease (formerly)
  • Hand-Schüller-Christian syndrome (formerly)
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

News & Events


ORDR Co-Sponsored Conferences

  • 2016 Rare Disease Day at NIH, Monday, February 29, 2016
    Location: Building 10, Masur Auditorium, National Institutes of Health, Bethesda, MD
    Description: The 2016 Rare Disease Day at NIH will take place on February 29. The event, sponsored by NCATS and the NIH Clinical Center, aims to raise awareness about rare diseases, the patients they affect and the research collaborations that are addressing rare disease challenges. The day will feature tours, posters and exhibits, and presentations.

  • Third International Meeting on Genetic Syndromes of the Ras/MAPK Pathway , Friday, August 02, 2013 - Sunday, August 04, 2013
    Location: Renaissance Orlando at SeaWorld, Orlando, FL

  • Clinicopathologic Overlap Between Rare Eosinophilic Disorders: Implications for Clinical Trial Design, Wednesday, July 17, 2013
    Location: Oxford, England
    Description: The short-term goals of the workshop are: 1) to bring together a multidisciplinary group of clinician-scientists with expertise in rare eosinophilic disorders to discuss issues related to improved clinical trial design, including the utility of current diagnostic criteria and the validation of biomarkers of disease activity, 2) to continue fostering collaborative relationships between multidisciplinary clinical and basic science researchers interested in eosinophilic disorders, and 3) to provide a venue for establishing a formal multidisciplinary clinical subgroup of the IES. It is anticipated that the findings from this workshop will lead to improved design of multicenter clinical trials to assess the safety and efficacy of novel agents for the treatment of these disorders. Furthermore, establishing a formal clinical subgroup of IES will facilitate advocacy for new clinical trials for rare eosinophilic disorders.

  • 8th International Eosinophil Society’s Biennial Symposium, Saturday, July 13, 2013 - Wednesday, July 17, 2013
    Location: Oxford, England
    Description: IES Symposium organizers’ central goal is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of allergy, immunology, hematology, and cancer in relation to the role of the eosinophil in health and disease.

  • 27th Histiocyte Annual Society Meeting, Monday, October 17, 2011 - Wednesday, October 19, 2011
    Location: Vienna, Austria
    Description: The annual Histiocyte Society (HS) meeting is a unique event in the world – the only opportunity to intensively focus on the many aspects of these rare disorders.

  • Overcoming Barriers to International Clinical Trials for Rare Cancers , Friday, December 10, 2010
    Location: Bethesda, Maryland
    Description: The goals of this conference were to introduce key institutional players to the topic of international clinical trials in rare cancers and to establish an ongoing dialogue. Participants left the meeting with a set of specific priorities that need to be enacted to promote these trials. The meeting promoted consensus on the way that resources are prioritized to address rare cancers. Participants were asked to convey the content of the meeting to their constituencies and to follow up with pilot concepts.

Other Names for this Disease
  • LCH
  • Histiocytosis X
  • Eosinophilic granuloma (formerly)
  • Letterer-Siwe disease (formerly)
  • Hand-Schüller-Christian syndrome (formerly)
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.